secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001493152-24-031463
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate Q2 net loss narrows to $3.2M; FDA clears NDA filing for ADHD drug CTx-1301
--------------------------------------------------------------------------------

- Net loss of $3.2M in Q2 2024 vs $6.6M in Q2 2023; R&D expenses fell to $1.9M from $4.5M YoY.
- Cash and equivalents $0.4M at June 30; received $1.6M net proceeds from warrant inducement closed July 1.
- FDA confirmed remaining clinical requirements; NDA submission for CTx-1301 targeted for first half 2025.
- Completed 1-for-12 reverse stock split on Aug 9 to regain compliance with Nasdaq $1.00 bid price rule.
- Commissioned payer study (10 payers, 121M lives) found CTx-1301 likely to gain coverage; licensing discussions ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315224031463/0001493152-24-031463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315224031463/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer